Bertil Lindmark

Global Vice President

Astra-Zeneca
bertil.e.lindmark(at)astrazeneca.com

 

 

 

Education

Medical School at Lund University, M.D. in 1980.

Board qualified Internal Medicine 1987

Board qualified Gastroenterology 1989

Ph. D. 1990, Lund University

Clinical Positions

Internship at Malmö General hospital 1980-1981, licensed 1981

Registrar at the Department of Medicine, Malmö General Hospital 1981-1987

Consultant at the Department of Medicine,  Section of Gastroenterology and, Malmö General Hospital 1988-1991

Pharmaceutical Industry Positions

Director at the Department of Clinical Safety Assessment, Astra Draco, Lund1991-96, renamed to Clinical Drug Safety and Epidemiology in 1997 and Drug Safety in 1999.

Director, Drug Safety, AstraZeneca, 1999

Director, Global Clinical Science, AstraZeneca R&D, Lund 2000

Site Head of Clinical Function and Director, Global Clinical Science, AstraZeneca R&D, Lund, 2000.

Therapeutic Area Medical Director, Respiratory and Inflammation Therapy Area (RITA) 2002.

VP Clinical RITA 2004, and current.

 

Professional Achievements

Managed Drug safety for AstraDraco between 1991 and 1999, developed processes, standards, databases and new concepts.

Written and implemented the Astra Drug Safety Strategy.

Written and supported Drug safety in all AstraDraco files between 1991 and 1999, including EU, US and Japanes files covering IBD, Allergic Rhinitis, Asthma and COPD, Renal Carcinoma and Hepatitis C indications.

Initiated 2 of the worlds largest asthma trials – the START study (7200 patients over 3 years), and the RELIEF study (18000 patients over 12 months).

Managed Medical Science in Lund for AstraZeneca, supported the Symbicort SMART concept, and development of Socity Impact Modelling.

Headed the AstraZeneca RITA strategy teams in Respiratory and Inflammation radically changing strategies and enabling portfolio risk change.

Accountable for all RITA projects and products from Clinical, designing early phase programs and documentative programa as well as activities supporting commercialisation, and product defebence.

Driven pharmacogenetics resulting in data on beta receptor subtypes in over 4000 patients.

Clinical Representative on the AstraZeneca Milestone 4 Committee (acceptance of molecules as CDs for AZ).

Network

Vast network in the epidemiology and drug safety worlds, also in Respiratory and Inflammation personal relation to the worlds leading respirologists and gastroenterologists.
LANGUAGE ABILITIES

Excellent written and spoken English, speaks both American and British English fluently, good stylist. Speaks Spanish and German to a slightly lesser extent on a conversational level. Slight knowledge of Japanese.

Specialist Fields

Specialist in internal medicine and gastroenterology. Expert knowledge in glucocorticosteroid and beta-2-agonist side effects, protease/antiprotease balance, alpha-1-antichymotrypsin. General knowledge in immunology and DNA-techniques and genetics.

Pharmaceutical industry drug safety, including regulations and reporting demands both pre- and post-approval from EU, FDA and MHLW perspectives.

Clinical Drug Development experience from respiratory (asthma, COPD, and rhinitis), GI, cancer, kidney disease, hepatitis C, both early and late stages including phase IV work and product defence.